WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 202960
Description: TL-310 is a new taxane analog that demonstrates potent antitumor activity in a variety of human cancer cell lines and in human tumor xenografts. The mechanism of action of TL-310 includes microtubule polymerization, resulting in a block in the G2/M phase of the cell cycle and programmed cell death (apoptosis). In the 786-0 human renal carcinoma model, oral TL-310 (80 mg/kg) was equally efficacious as IV administered paclitaxel or docetaxel. Orally administered TL-310 consistently maintained excellent antitumor efficacy which was well below its maximum tolerated dose in mice.
MedKoo Cat#: 202960
Chemical Formula: C45H55NO16
Exact Mass: 865.35208
Molecular Weight: 865.91
Elemental Analysis: C, 62.42; H, 6.40; N, 1.62; O, 29.56
TL-310 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to firstname.lastname@example.org to inquire quote.
Synonym: TL310; TL310; TL 310.
IUPAC/Chemical Name: 2-Furanpropanoic acid, .alpha.-hydroxy-.beta.-[[(2-methylpropoxy)carbonyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[(cyclopropylcarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (.alpha.R,.beta.R)-
SMILES Code: O=C(O[C@@H]1C(C)=C(C2(C)C)[C@@H](OC(C3CC3)=O)C([C@@]([C@@H](O)C4)(C)[C@]([C@@]5(OC(C)=O)[C@]4([H])OC5)([H])[C@H](OC(C6=CC=CC=C6)=O)[C@]2(O)C1)=O)[C@H](O)[C@@H](NC(OCC(C)C)=O)C7=CC=CO7
The following data is based on the product molecular weight 865.91 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
Singh, Chandra Ulagaraj. Solid nanoparticle formulation of water insoluble pharmaceuticals with reduced Ostwald ripening. PCT Int. Appl. (2008), 134pp. CODEN: PIXXD2 WO 2008013785 A2 20080131 CAN 148:198644 AN 2008:124314